These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29205263)

  • 1. LSD1 (KDM1A)-independent effects of the LSD1 inhibitor SP2509 in cancer cells.
    Sonnemann J; Zimmermann M; Marx C; Ebert F; Becker S; Lauterjung ML; Beck JF
    Br J Haematol; 2018 Nov; 183(3):494-497. PubMed ID: 29205263
    [No Abstract]   [Full Text] [Related]  

  • 2. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
    Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
    Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
    Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
    Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
    Zhen H; Zhang X; Zhang L; Zhou M; Lu L; Wu L; He N; Wang J; Li R; Guo Y
    Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):1098-1105. PubMed ID: 34169322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel LSD1 Inhibitor T-3775440 Disrupts GFI1B-Containing Complex Leading to Transdifferentiation and Impaired Growth of AML Cells.
    Ishikawa Y; Gamo K; Yabuki M; Takagi S; Toyoshima K; Nakayama K; Nakayama A; Morimoto M; Miyashita H; Dairiki R; Hikichi Y; Tomita N; Tomita D; Imamura S; Iwatani M; Kamada Y; Matsumoto S; Hara R; Nomura T; Tsuchida K; Nakamura K
    Mol Cancer Ther; 2017 Feb; 16(2):273-284. PubMed ID: 27903753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
    Sehrawat A; Gao L; Wang Y; Bankhead A; McWeeney SK; King CJ; Schwartzman J; Urrutia J; Bisson WH; Coleman DJ; Joshi SK; Kim DH; Sampson DA; Weinmann S; Kallakury BVS; Berry DL; Haque R; Van Den Eeden SK; Sharma S; Bearss J; Beer TM; Thomas GV; Heiser LM; Alumkal JJ
    Proc Natl Acad Sci U S A; 2018 May; 115(18):E4179-E4188. PubMed ID: 29581250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermolecular insights into allosteric inhibition of histone lysine-specific demethylase 1.
    Zhang X; Sun Y; Zhang Z; Wang H; Wang J; Zhao D
    Biochim Biophys Acta Gen Subj; 2021 Nov; 1865(11):129990. PubMed ID: 34390793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SP2509, a Selective Inhibitor of LSD1, Suppresses Retinoblastoma Growth by Downregulating β-catenin Signaling.
    Jiang A; Wu W; Xu C; Mao L; Ao S; Guo H; Sun X; Tao J; Sang Y; Huang G
    Invest Ophthalmol Vis Sci; 2022 Mar; 63(3):20. PubMed ID: 35297943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and in vitro evaluation of stilbene derivatives as novel LSD1 inhibitors for AML therapy.
    Duan Y; Qin W; Suo F; Zhai X; Guan Y; Wang X; Zheng Y; Liu H
    Bioorg Med Chem; 2018 Dec; 26(23-24):6000-6014. PubMed ID: 30448189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.
    Liu H; Wei J; Sang N; Zhong X; Zhou X; Yang X; Zhang J; Zuo Z; Zhou Y; Yang S; Du J; Zhao Y
    Med Oncol; 2021 Sep; 38(10):124. PubMed ID: 34491469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies reveal that LSD1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations.
    Macheleidt IF; Dalvi PS; Lim SY; Meemboor S; Meder L; Käsgen O; Müller M; Kleemann K; Wang L; Nürnberg P; Rüsseler V; Schäfer SC; Mahabir E; Büttner R; Odenthal M
    Mol Oncol; 2018 Nov; 12(11):1965-1979. PubMed ID: 30220105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LSD1/KDM1A inhibitors in clinical trials: advances and prospects.
    Fang Y; Liao G; Yu B
    J Hematol Oncol; 2019 Dec; 12(1):129. PubMed ID: 31801559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comprehensive review of lysine-specific demethylase 1 and its roles in cancer.
    Hosseini A; Minucci S
    Epigenomics; 2017 Aug; 9(8):1123-1142. PubMed ID: 28699367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia.
    Przespolewski A; Wang ES
    Expert Opin Investig Drugs; 2016 Jul; 25(7):771-80. PubMed ID: 27077938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.
    Deb G; Wingelhofer B; Amaral FMR; Maiques-Diaz A; Chadwick JA; Spencer GJ; Williams EL; Leong HS; Maes T; Somervaille TCP
    Leukemia; 2020 May; 34(5):1266-1277. PubMed ID: 31780813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience-based discovery (EBD) of aryl hydrazines as new scaffolds for the development of LSD1/KDM1A inhibitors.
    Li ZR; Wang S; Yang L; Yuan XH; Suo FZ; Yu B; Liu HM
    Eur J Med Chem; 2019 Mar; 166():432-444. PubMed ID: 30739825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Annual review of LSD1/KDM1A inhibitors in 2020.
    Fu DJ; Li J; Yu B
    Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia.
    Johnston G; Ramsey HE; Liu Q; Wang J; Stengel KR; Sampathi S; Acharya P; Arrate M; Stubbs MC; Burn T; Savona MR; Hiebert SW
    Gene; 2020 Aug; 752():144758. PubMed ID: 32422235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting LSD1 for acute myeloid leukemia (AML) treatment.
    Zhang S; Liu M; Yao Y; Yu B; Liu H
    Pharmacol Res; 2021 Feb; 164():105335. PubMed ID: 33285227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.